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Background/aim: To investigate the similarities and differences of renal clinical and renal pathology between IgA nephropathy (IgAN)
and IgA vasculitis nephritis (IgAVN) in children.
Materials and methods: A total of 237 children with IgAN and 190 children with IgAVN were included. The general conditions, clinical
characteristics, final diagnosis, clinical and pathological classification of the children were intercepted at the time of admission, and the
retrospective comparative analysis was carried out.
Results: The results showed that the median course of disease in IgAN group was longer than that in IgAVN group (p = 0.02). Patients
with IgAN had a significantly higher duration of infection than the patients with IgAVN (p = 0.03). The white blood cell count (WBC),
hemoglobin (HGB) in IgAN group were significantly lower than that in IgAVN group (p = 0.02). The serum creatinine in IgAN group
was higher than that in IgAVN group (p = 0.02). Patients with IgAN and IgAVN had statistically significant differences in pathological
typing between clinical types: hematuria and proteinuria, nephrotic syndrome and chronic nephritis (p = 0.004).
Conclusion: The clinical manifestations of IgAN and IgAVN were similar, but the onset of IgAN was hidden and the clinical manifestations
were relatively serious. Renal pathology was mainly glomerulosclerosis and renal tubular atrophy. IgAVN was characterized by acute
onset and good renal function. Renal pathology was dominated by endothelial hyperplasia and crescent formation. These differences
did not support the hypothesis that the two diseases are the same.
Key words: IgA nephropathy, IgA vasculitis nephritis, children, clinical and pathological features of kidney, anaphylactoid purpura

1. Introduction
Anaphylactoid purpura, also known as IgA vasculitis
nephritis (IgAV) was a systemic small vasculitis that can
cause damage to multiple organs. Most of the cases occur
in children aged 2–8 years, with more boys than girls. IgA
vasculitis nephritis (IgAVN) was found in 30% to 60% of
the cases [1]. It was characterized by varying degrees of
hematuria and/or proteinuria, and the symptoms vary in
severity, and there was no consistent relationship with the
severity of extrarenal symptoms. In general, the prognosis
of hematuria and mild proteinuria under the microscope
was good. About 20% of IgAVN presents with nephrotic
syndrome, and its prognosis was poor, which can lead to
end-stage renal failure [1,2].
In the 2012 Chapel Hill conference, it was proposed
to name anaphylactoid purpura directly as IgA vasulitis
(IgAV), and it was pointed out that systemic vasculitis
may develop from organ specific vasculitis. There was

no difference between IgAVN and IgAN, and both were
a component of IgAV [3]. The initiating factor of the
pathogenesis of the two was the abnormal glycosylation of
IgA1 [4], and the renal pathology of the two was the same
[5,6]. The main pathological types of both IgAVN and
IgAN were mesangial proliferative glomerulonephritis and
focal proliferative glomerulonephritis [7]. At present, it is
considered that the pathophysiology of IgAVN and IgAN
was similar, and C3 can be seen in 75%–100% of IgAVN
and IgAN patients [8]. This study was to investigate the
similarities and differences of renal clinical and renal
pathology between IgAN and IgAVN in children.
2. Materials and methods
2.1. Research subjects
In this study, 237 children with IgAN and 190 children
with IgAVN were included. Participants had been divided
into IgAN group and IgAVN group. The diagnostic criteria,
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clinical classification, and pathological classification of
IgAN and IgAVN were based on the standards of the
Nephrology Group of the Pediatric Branch of the Chinese
Medical Association [5,6]. This study was conducted in
accordance with the Declaration of Helsinki and approved
by the ethics committee of our hospital.
2.2. Inclusion and exclusion criteria
Inclusion criteria: (1) Research subjects ≤18 years old; (2)
The patients in this study were hospitalized in the Second
Hospital of Hebei Medical University from January 2010
to December 2019, and were diagnosed with IgAN and
IgAVN by renal biopsy. Exclusion criteria: (1) patients
who have had other renal or nonrenal diseases; (2) patients
whose data was incomplete.
2.3. Methods
Pathological grading: The pathological grading of IgAN
was I–W according to Lee’s grading standard in 1982 [9].
The pathological grading of IgAVN was I–WI according to
the grading standard of the International Study of Kidney
Disease in Children (ISKDC) [10]. Oxford pathology
classification was based on the newly revised Oxford
classification method in 2017, namely MEST-C [11].
Clinical classification: According to the IgAN
classification standard and IgAVN classification standard
established by the Nephrology Group of the Pediatrics
Branch of the Chinese Medical Association in 2016
[5,6]. According to whether the patients have hematuria,
proteinuria, and nephritis symptoms, the patients were
divided into hematuria and proteinuria type, acute nephritis
type, nephrotic syndrome type, isolated hematuria type,
chronic nephritis type, isolated proteinuria type and
rapidly progressive nephritis type.
2.4. Main observation indicators
The demographic data, laboratory test items, clinical
manifestations, and renal pathology of the patient at the
first visit were included. Demographic data included
age, sex, body mass index BMI (kg/m2). Laboratory
examination items included white blood cell count
(WBC), hemoglobin (HGB), platelets (PLT), 24-h urine
protein, urine red blood cell count, blood urea nitrogen,
serum albumin, total cholesterol, blood creatinine,
immunoglobulin, complement and glomerular filtration
rate. Renal pathology included light microscopy,
immunofluorescence, the proportion of glomerular
sclerosis, the proportion and type of crescent, loop
necrosis, mesangial hyperplasia, endothelial hyperplasia,
interstitial inflammation, tubule atrophy, IgM, IgG, IgA,
C3, C1Q.
2.5. Statistical analysis
We used the software program SPSS 26.0 (IBM, Armonk,
NY, USA) to conduct the statistical analysis. The continuous
variables of normal distribution were expressed as mean ±
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standard deviation, the continuous variables of nonnormal
distribution were expressed as median [interquartile
range (IQR)], the categorical variables were expressed as
frequency [percentage (%)]. For two comparisons, each
value was compared by t-test when each datum conformed
to normal distribution, while the nonnormally distributed
continuous data were compared using nonparametric
tests. The counting data were tested by chi-square test. A
value of p < 0.05 was considered statistically significant.
3. Results
3.1. General characteristics
In this study, a total of 237 children with IgAN and 190
children with IgAVN were included. The screening process
was shown in Figure. We screened out the cases preserved
in our hospital, selected the patients who were treated
in our hospital from January 2010 to December 2019,
excluded the patients who were older than 18 years old
and had incomplete data, and finally met the conditions of
237 patients with IgAN and 190 patients with IgAVN. In
the IgAN group, there were 151 males and 86 females, the
mean ± SD of age was 13.3 ± 2.3, the mean ± SD of BMISDS was 1.32 ± 0.25. In the IgAVN group, there were 106
males and 84 females, the mean ± SD of age was 13.2±3.1,
the mean ± SD of BMI-SDS was 1.29 ± 0.38. The results
showed that there was no significant difference in the age
of onset and age distribution (<6 years; 6–12 years; >12
years), sex and BMI-SDS index between the two groups.
3.2. Clinical manifestations and laboratory tests
The median course of onset in the IgAN group was
significantly longer than that of IgAVN. The IgAN group
had a higher proportion of prodromal infection history
than the IgAVN group (p = 0.03). There was no significant
difference in family history, systolic blood pressure,
diastolic blood pressure, and mean arterial blood pressure
(MAP). The median courses of onset were listed in the
Table 1.
The clinical classification of two groups of diseases in
children were shown in the Table 2. There were significant
differences in isolated proteinuria, nephrotic syndrome,
acute nephritis and chronic nephritis between the two
groups (p = 0.004). There were no statistically significant
differences in hematuria and proteinuria, isolated
hematuria, and acute progressive nephritis (p = 0.10).
There was no statistical difference in platelet count,
glomerular filtration rate, urine red blood cell count,
24-h urine protein, serum globulin, serum cholesterol,
serum complement C3, C4 and serum immunoglobulin
between IgAN group and IgAVN group. The serum
immunoglobulin IgA in two groups was higher than
normal. The details were listed in the Table 3.
Among the various clinical types of IgAN and IgAVN,
the most common pathological types were type II and
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Figure. Flow chart of case screening in IgAN and IgAVN groups.
Table 1. Comparison of general clinical characteristics between IgAN group and IgAVN group.
Index

IgA nephropathy
(n = 237)

IgA vasculitis nephritis
(n = 190)

p

Age (year)

13.3 ± 2.3

13.2 ± 3.1

>0.05

>12

124 (52.3%)

100 (52.6%)

>0.05

6~12

96 (40.5%)

66 (34.7%)

>0.05

<6

17 (7.2%)

24 (12.7%)

>0.05

Male

151 (63.7%)

106 (50.5%)

>0.05

Female

86 (36.3%)

84 (49.5%)

Height-SDS

0.78 ± 1.28

0.82 ± 1.41

>0.05

BMI-SDS

1.32 ± 0.25

1.29 ± 0.38

>0.05

SBP-SDS

0.28 ± 0.12

0.31 ± 0.19

>0.05

DBP-SDS

0.33 ± 0.13

0.36 ± 0.18

>0.05

Median course of disease (months)

1.4 (0.63–8)

0.67 (0.33–3)

0.02

Family history

3 (1.3%)

8 (4.2%)

>0.05

History of precursor infection

134 (56.5%)

68 (35.8%)

0.03

Sex

type III, followed by type I and type IV. No cases of type
V in the pathological classification and type VI in IgAVN
were observed in two groups. There were statistically
significant differences between IgAN group and IgAVN
group in pathological classification among the three
different clinical types of chronic nephritis, hematuria
and proteinuria and nephrotic syndrome [α2 =136.56, p =
0.004, C2 = 25.156, P = 0.008].

3.3. Renal pathology
The results showed that the renal pathology of the two
groups showed no statistically significant differences in the
proportion of glomerular sclerosis (including the proportion
of spherical sclerosis and the proportion of segmental
sclerosis), the degree of mesangial cell proliferation,
the proportion of loop necrosis, and the proportion of
interstitial cell infiltration (p = 0.08). The proportion of
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Table 2. The clinical classification of two groups.
Index

IgA nephropathy
(n = 237)

IgA vasculitis nephritis
(n = 190)

p

Nephrotic syndrome type

81 (34.2%)

36 (19.0%)

0.004

Hematuria proteinuria type

84 (35.4%)

70 (36.8%)

0.004

Chronic nephritis type

54 (22.8%)

27 (14.2%)

0.004

Isolated hematuria type

9 (3.8%)

14 (7.4%)

>0.05

Acute nephritis type

5 (2.1%)

22 (11.6%)

>0.05

Isolated proteinuria type

3 (1.3%)

20 (10.5%)

>0.05

Acute progressive nephritis type

1 (0.4%)

1 (0.5%)

>0.05

Table 3. Comparison of laboratory indexes between two groups of children.
Index

IgAN
(n = 237)

IgAVN
(n = 190)

p

WBC (×109/L)

8.4 ± 4.5

10.2 ± 4.5

0.02

Hb (g/L)

126 ± 15.7

133.6 ± 16.15

0.02

PLT (×109/L)

290.0 ± 89.5

300.7 ± 84.6

>0.05

Hematuria (/uL)

3306 ± 6326.3

530.3 ± 822.5

>0.05

Proteinuria (g/24 h)

2.5 ± 2.3

1.9 ± 1.8

>0.05

Scr (umol/L)

70.7 ± 54.5

58.4 ± 17.6

0.02

eGFR (mL/min/1.73 m2)

146.2 ± 133.0

155.0 ± 130.6

>0.05

Alb (g/L)

32.6 ± 8.6

33.1 ± 8.7

>0.05

Chol (mmol/L)

4.9 ± 2.1

4.5 ± 1.6

>0.05

IgA (g/L)

2.3 ± 1.0

2.2 ± 0.9

>0.05

IgG (g/L)

7.1 ± 3.4

7.3 ± 4.4

>0.05

IgM (g/L)

1.2 ± 0.7

1.2 ± 0.6

/

C3 (mg/dL)

101.3 ± 25.8

102.5 ± 26.7

>0.05

C4 (mg/dL)

23.3 ± 8.9

22.8 ± 11.3

>0.05

tubule atrophy in the IgAN group was significantly higher
than that in the IgAVN group [132 (55.7%) vs. 17 (8.9%)],
while the proportion of endothelial hyperplasia and
crescent formation in the IgAN group was lower than that
in the IgAVN group [41(17.3%) vs. 64 (34.7%), 56 (23.6%)
vs. 71 (37.4%)], the difference was statistically significant.
Immunofluorescence results showed that both groups
had IgA immune complex deposition in the mesangial area,
most of which are accompanied with C3 deposition, often
accompanied with IgM deposition, a small part with IgG
deposition, and rarely with Fibrogen and C1q deposition.
There was no significant difference in the distribution
of IgG, C3, and C1q deposition in immunofluorescence
between the two groups of diseases. The distribution of
IgM, C4, and Fibrogen deposition in the IgAN group
was significantly lower than that in the IgAVN group [41
(17.3%) vs. 58 (30.5%), 6 (2.5%) vs. 26 (13.7%), 6 (2.5%) vs.
26 (13.7%)], and the difference was statistically significant
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(p = 0.003). There was no statistically significant difference
in deposition type in IgA+C3, IgA+IgM/C3, IgA+IgG.
However, the IgAN group was significantly higher in
IgA+IgM+IgG/C3 than the IgAVN group [39 (16.5%) vs.
18(9.4 %)] (p = 0.03). The details were listed in the Table 4.
Oxford classification of renal pathology results showed
that mesangial cells (M), endothelial hyperplasia (E),
segmental glomerulosclerosis (S), renal tubular atrophy
(T) and crescent formation (C) in the two groups were
statistically analyzed. There was no significant difference in
mesangial cells (M) between the two groups. The ratio of
S1 and T1/T2 in the IgAN group was significantly higher
than that in the IgAVN group [84 (35.4%) vs. 42 (22%), 98
(41.4%)/34 (14.3%) vs.15 (7.9%)/2 (1.0%)], while the ratio
of crescent formation C2/C1 and E1 in the IgAN group was
lower than that in the IgAVN group [32 (13.5%)/24 (20.1%)
vs. 40 (21.1%)/31(16.3%), 41(17.3%) vs. 64 (34.7 %)]. The
details were listed in the Table 4.

SU et al. / Turk J Med Sci
Table 4. Renal pathological immunofluorescence manifestations and Oxford typing of renal pathology between two groups.
Index

IgAN (n = 237)

IgAVN (n = 190)

p

IgM
IgG
IgA
C3
Fibrogen
C1q
Deposition type
IgA+C3
IgA+IgM/C3
IgA+IgG
IgA+IgM+IgG/C3
M (0/1)
E (0/1)
S (0/1)
T (0/1/2)
C (0/1/2)

41 (17.3%)
19 (8.0%)
237 (100%)
201 (84.8%)
6 (2.5%)
7 (3.0%)

58 (30.5%)
10 (5.3%)
190 (100%)
158 (83.2%)
26 (13.7%)
7 (3.7%)

0.003
>0.05
/
>0.05
0.003
>0.05

68 (28.7%)
125 (52.7%)
5 (2.1%)
39 (16.5%)
138 (58.2%)/99 (41.8%)
196 (82.7%)/41 (17.3%)
153 (64.6%)/84 (35.4%)
105 (44.3%)/98 (41.4%)/34 (14.3%)
181 (76.4%)/32 (13.5%)/24 (10.1%)

63 (33.2%)
105 (55.3%)
4 (2.1%)
18 (9.4%)
114 (60.0%)/76 (40.0%)
124 (65.3%)/64 (34.7%)
148 (78%)/42 (22%)
173 (91.1%)/15 (7.9%)/2 (1.0%)
119 (62.6%)/40 (21.1%)/31 (16.3%)

>0.05
>0.05
>0.05
0.03
>0.05
0.003
0.003
0.003
0.02

4. Discussion
IgAN and IgAVN were respectively one of the common
primary and secondary glomerular diseases in pediatrics
[12,13]. IgAN and IgAVN were characterized by mesangial
IgA deposition in renal tissue immunopathology, which
cannot be distinguished by renal pathology. Therefore,
some scholars have proposed that IgAN was IgAVN
without skin rash [14], and both of them have common
pathogenesis [15]. But are they the same disease? Some
studies had explored the clinical manifestations, pathology,
diagnostic and prognostic markers of IgAN and IgAVN, so
as to explore the differences. But in the absence of large
studies, including adults and children from different
geographical part of the world, suffering from IgAN or
IgAVN with or without renal impairment, it is not yet
possible to conclude on their differences or similarity in
terms of prognosis and sensitivity to treatment [16]. In
this study, the clinical manifestations and pathology of
IgAN and IgAVN were compared to find the differences
and provided the basis for diagnosis and treatment. This
study showed that in the demographic data, there was no
significant difference in the median age, age distribution,
sex and BMI of children with IgAN and IgAVN. The
median course of IgAN was significantly longer than that
of IgAVN. IgAN was insidious and some children had
asymptomatic onset. However, about 75% of children with
IgAV had kidney damage within 4 weeks of onset, and
more than 95% of children with IgAV had kidney damage
within 6 months [17]. With the improvement of medical
conditions, patients’ awareness of follow-up visits has
increased, shortening the median course of IgAVN.

In this study, the two groups of diseases had similar
clinical manifestations, and the same clinical classification
methods were used. The clinical types of the IgAN
group were mainly hematuria proteinuria and nephrotic
syndrome, and the two types accounted for more than 2/3 of
the total cases. In the IgAVN group, hematuria proteinuria
and nephrotic syndrome were also the most common,
accounting for 55.8% of the total cases. The two types
accounted for 55.8% of the total number of cases. IgAN
in nephrotic syndrome type cases and its constituent ratio
were significantly higher than IgAVN, which suggested
that IgAN was more serious than IgAVN. The main clinical
types of the two groups of diseases were quite different
from domestic studies. In the two groups of diseases,
chronic nephritis, isolated hematuria and nephrotic
syndrome was the most common [18–20]. In this study,
isolated proteinuria was found in IgAN and IgAVN clinical
classification, which accounted for 3 cases (1.3%) and
20 cases (10.5%) respectively, which was similar to some
domestic studies [20]. Although in this study the research
objects were the first diagnosed cases in our hospital, there
were also repeated visits outside the hospital, both types
of cases have chronic nephritis. The main clinical types
of this study were different from those of other research
centers. The reasons were as follows: (1) the indications of
renal puncture were different; (2) the level of diagnosis and
treatment in the hospital and the compliance of patients
were different; (3) there may be regional differences due to
small sample size and selection bias.
For the pathological types of IgAN and IgAVN, the
results of this study showed that type III and type II
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were more common, and the difference in pathological
grading between different clinical types was statistically
significant. The reasons may be as follows: (1) Clinical
classification and pathological grading were not parallel;
(2) In laboratory indicators, urine red blood cell count,
urine protein, and blood pressure were involved in the
disease and lead to different levels of renal pathological
changes; the pathological changes of IgAN and IgAVN
were similar. Immunofluorescence is mainly characterized
by IgA deposition in the mesangial area of the glomerulus
or the deposition of immune complexes dominated by
IgA deposition, and it can also be manifested as mesangial
hyperplasia and crescent formation. In this study,
inflammatory cell infiltration was more common in the
IgAN group than in the IgAVN group, and tubule atrophy
and loop necrosis in the IgAN group were more obvious
than those in the IgAVN group, suggesting that the degree
of chronicity of IgAN renal pathology was obvious, and
IgAVN was more serious in endothelial hyperplasia and
crescent formation than IgAN. IgAVN showed an acute
pathological process, which can be reversed by active and
effective treatment. This was consistent with domestic and
foreign reports [21,22].
This study also carried out renal pathological
assessment on the IgAN group and IgAVN group
according to Oxford classification, and concluded that M1,
E1, S1, T1/2, and C1/2 were relatively common in IgAVN.
Among them, endothelial cell proliferation and crescent
formation are the most common, which was consistent
with the results of Koji Inagaki et al. in Japan [23]. This
suggested that the five classification indicators of MEST-C
of Oxford classification may be applied to IgAVN. Not
only can the prognosis of IgAVN be judged according to
the pathological type, but also the primary and secondary
glomerulonephritis dominated by IgA can adopt a unified
standard. In this study, the formation of IgAVN crescent
was more serious than IgAN. However, the overall kidney
damage and renal function of IgAN were worse. Crescent
may cause glomerular scarring, which was related to
decreased renal function. However, this damage may
be short-lived and can be reversal. The proportion of
crescents in Oxford classification was the sum of large
and small crescents, not the large or small crescents alone,
which weakens its independent predictive effect, so it may
not be an indicator of long-term prognosis. Yu Lei et al.
[24] found that there was a strong correlation between the
degree of renal tubule-interstitial lesions and prognosis.
IgA has a poor prognosis and severe interstitial damage is
one of the reasons. In this study, the ratio of S1 and T1/2
in the IgAN group was significantly higher than that in the
IgAVN group, and the inflammatory cell infiltration was
more obvious, which was consistent with the study of Yu
Lei et al.
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Leukocyte and hemoglobin in IgAN group were
significantly lower than those in IgAVN group, and
serum creatinine was significantly higher than those in
IgAVN group; the clinical manifestations of children in
IgAN group were more serious. The renal pathology of
children in IgAN group is mainly glomerulosclerosis and
renal tubular atrophy. The renal pathology of children
in IgAVN group is endothelial hyperplasia and crescent
formation. The renal pathological changes of children in
IgAN group are also more serious than those in IgAVN
group. The clinical and laboratory indexes are consistent
with the renal pathological manifestations, and the two
may be related. The more specific relationship between the
clinical and laboratory indexes are consistent with the renal
pathological manifestations needs further research.
Limitations: First, this was a retrospective study, in which
some cases were eliminated due to incomplete data, which
had a certain impact on the results. Second, physicians had
different perception of the indications for renal puncture.
Third, the two clinical entities had different classification
methods: IgAVN’s International Research Classification of
Kidney Diseases in Children (ISKDC) classification and
IgAN’s Lee classification. The measurement standards were
not unified. When comparing the pathological grading of
the two groups of diseases in the same clinical type, the
conclusion was different from the actual. Fourth, although
current studies had found that almost all children with
IgAN have more severe clinical diagnosis than IgAVN in
all age groups, but the relationship between the severity of
diagnosis and pathological types cannot be investigated.
Fifth, lack of comparison of final outcomes, including
hypertension, GFR and ESRD (end stage renal disease) or
dialysis necessity. This may cause the result analysis to be
not deep enough and the conclusion to be not perfect.
Conclusion: The clinical manifestations of IgAN and
IgAVN were similar, but the onset of IgAN was hidden
and the clinical manifestations were relatively serious.
Clinical manifestations was mainly glomerulosclerosis and
renal tubular atrophy. IgAVN was characterized by acute
onset and good renal function. Clinical manifestations
was dominated by endothelial hyperplasia and crescent
formation. These differences do not support the hypothesis
that the two diseases are the same.
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